CoChat
Sign Up
Cited by 191Adipose Tissue and MetabolismAdipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.

Weyer, C, Tataranni, P A, Snitker, S, Danforth, E, Ravussin, E·1998·Diabetes
DOI 10.2337/diabetes.47.10.1555
Open this paper in CoChat — free account

Abstract

Stimulation of beta3-adrenoceptors by selective agonists improves insulin action and stimulates energy metabolism in various rodent models of obesity and type 2 diabetes. Whether selective beta3-adrenoceptor stimulation exerts metabolic actions in humans remains to be proven. The effects of a highly selective beta3-adrenoceptor agonist on insulin action, energy metabolism, and body composition were assessed in 14 healthy young lean male volunteers (age 22.5 +/- 3.3 years, 15 +/- 5% body fat [mean +/- SD]) randomly assigned to 8 weeks of treatment with either 1,500 mg/day of CL 316,243 (n = 10) or placebo (n = 4). Insulin-mediated glucose disposal (IMGD), nonoxidative glucose disposal (NOGD), oxidative glucose disposal (OGD) (indirect calorimetry), and splanchnic glucose output (SGO; beta3-[H3]glucose) were determined during a 100-min hyperinsulinemic-euglycemic glucose clamp (40 mU x m(-2) x min(-1)) before and after 4 and 8 weeks of treatment. The 24-h energy expenditure (24-EE), 24-h respiratory quotient (24-RQ), and the oxidation rates of fat and carbohydrate were determined in a respiratory chamber before and after 8 weeks. After 4 weeks, treatment with CL 316,243 increased IMGD (+45%, P < 0.01) in a plasma concentration-dependent manner (r = 0.76, P < 0.02). This effect was due to an 82% increase in NOGD (P < 0.01), while OGD and SGO remained unchanged. The effects on insulin action were markedly diminished after 8 weeks; this was significantly related to an unexpected decline in the plasma concentrations of CL 316,243 (-36%, P = 0.08). At this time, 24-RQ was lowered (P < 0.001), corresponding to a 23% increase in fat oxidation (P < 0.01) and a 17% decrease in carbohydrate oxidation (P = 0.05). The 24-EE after 8 weeks did not differ from baseline, and there was no change in body weight or body composition. Plasma concentrations of glucose, insulin, and leptin were unaffected by treatment, while free fatty acid concentrations increased by 41% (P < 0.05), again linearly with the achieved plasma concentration of CL 316,243 (r = 0.67, P < 0.05). Treatment with CL 316,243 had no effect on heart rate or blood pressure and caused no cases of tremors. We conclude that treatment of lean male subjects with CL 316,243 increases insulin action and fat oxidation, both in a plasma concentration-dependent manner. This is the first study to demonstrate unequivocal metabolic effects of a highly selective beta3-adrenoceptor agonist in humans.

Overview

Integrity signals

Registry

Crossref · 10.2337/diabetes.47.10.1555

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 13 references

Cited by

Sorted by citations

Items 101–191 of 191

Related

See all

Metadata

Authors
Weyer, C., Tataranni, P. A., Snitker, S., Danforth, E., & Ravussin, E.
Affiliations
  • National Institutes of Health (US)
  • Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA. cweyer@phx.niddk.nih.gov
ORCID
Snitker, S
Venue
Diabetes
Publisher
American Diabetes Association
Published
1998-10-01
Volume
47
Issue
10
Pages
1555-1561
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
DOI
10.2337/diabetes.47.10.1555
OpenAlex
W2090592868
Cited by
188
References
13
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 8 · 2021: 8 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 9 · 2016: 12 · 2015: 12 · 2014: 6 · 2013: 4 · 2012: 5
FWCI
7.36
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
CL316,243, beta3-adrenergic agonists, insulin action, insulin-stimulated glucose disposal, nonoxidative glucose disposal, fat oxidation, carbohydrate oxidation, respiratory quotient, energy expenditure, body composition, plasma drug concentration, type 2 diabetes, obesity, energy metabolism
MeSH terms
Adrenergic beta-Agonists, Adult, Blood Glucose, Body Composition, Body Weight, Dioxoles, Double-Blind Method, Energy Metabolism, Fatty Acids, Nonesterified, Humans, Insulin, Male, Oxidation-Reduction, Proteins, Glucose Clamp Technique, Leptin, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review